CorMedix Inc. CRMD
NASDAQ · Vereinigte Staaten · Gesundheitstechnologie
$7,19-0,23 (-3,10 %)
Markt geschlossen· · USD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Markt geschlossen· · USD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
On August 13, CorMedix (NASDAQ:CRMD) reported second quarter revenue of $101.9 million, more than double what it posted a year earlier, alongside net income of $26 million and adjusted EBITDA of $58.7 million, nearly triple the prior year’s figure. Management also raised its full year adjusted EBITDA outlook. Yet full year revenue guidance stayed exactly […]
PARSIPPANY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that senior management will be participating in a fireside chat and investor meetings at the upcoming Wells Fargo 21st Annual Healthcare Conference being held in Boston on September 8 – 10, 2026. Wells Fargo 21st Annual Healthcare ConferenceDate:Time:Webca
Moby summary of CorMedix Inc.'s Q2 2026 earnings call
DefenCath sales and the Melinta portfolio drive a 157% revenue surge, while a new LDO agreement expands market reach.
CorMedix expects to submit its supplemental Rezzayo application in Q3, with a potential FDA decision in the first half of 2027.
‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced financial results for the second quarter ended June 30, 2026, and provided an update on its business. Recent Corporate Highlights:
PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026, and will host a corporate update conference call at 8:30am Eastern Time. Thursday, August 13th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Webcast:Webcast Link About CorMedixCorMedix Therapeutics is a biopharmaceutical company focused on
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.